Artisan Partners Limited Partnership Sells 1,670 Shares of Bio-Rad Laboratories, Inc. $BIO

Artisan Partners Limited Partnership cut its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 1.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 118,198 shares of the medical research company’s stock after selling 1,670 shares during the period. Artisan Partners Limited Partnership owned 0.44% of Bio-Rad Laboratories worth $28,524,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Victory Capital Management Inc. raised its position in Bio-Rad Laboratories by 33.9% in the 1st quarter. Victory Capital Management Inc. now owns 29,742 shares of the medical research company’s stock worth $7,244,000 after purchasing an additional 7,525 shares during the period. Allianz Asset Management GmbH bought a new position in shares of Bio-Rad Laboratories in the 1st quarter worth about $3,981,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Bio-Rad Laboratories in the 1st quarter worth approximately $206,000. Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in shares of Bio-Rad Laboratories by 1.0% during the first quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 10,745 shares of the medical research company’s stock valued at $2,617,000 after acquiring an additional 108 shares in the last quarter. Finally, Oak Thistle LLC bought a new position in shares of Bio-Rad Laboratories in the first quarter worth approximately $259,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Insider Transactions at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, EVP James Barry sold 700 shares of Bio-Rad Laboratories stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $306.18, for a total value of $214,326.00. Following the completion of the transaction, the executive vice president owned 510 shares of the company’s stock, valued at approximately $156,151.80. The trade was a 57.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 17.06% of the company’s stock.

Analyst Upgrades and Downgrades

BIO has been the topic of several research reports. Citigroup raised their target price on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Zacks Research raised Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 26th. Royal Bank Of Canada lifted their price objective on Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an “outperform” rating in a report on Friday, August 1st. Wells Fargo & Company upped their price objective on Bio-Rad Laboratories from $265.00 to $340.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Finally, Wall Street Zen downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Saturday. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Bio-Rad Laboratories has a consensus rating of “Hold” and an average target price of $358.50.

Bio-Rad Laboratories Price Performance

BIO opened at $316.92 on Friday. The stock has a market cap of $8.55 billion, a P/E ratio of -13.04 and a beta of 1.04. The business has a fifty day moving average of $304.72 and a 200 day moving average of $272.22. Bio-Rad Laboratories, Inc. has a 52-week low of $211.43 and a 52-week high of $373.69. The company has a quick ratio of 3.67, a current ratio of 5.12 and a debt-to-equity ratio of 0.17.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Wednesday, October 29th. The medical research company reported $2.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.30 by ($0.04). Bio-Rad Laboratories had a negative net margin of 26.43% and a positive return on equity of 4.18%. The business had revenue of $653.00 million for the quarter, compared to analysts’ expectations of $651.30 million. During the same period in the previous year, the business earned $2.01 earnings per share. The business’s quarterly revenue was up .5% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.